

FAPESP 203 US (10026221)

RECEIVED
CENTRAL FAX CENTER

AUG 06 2007

REMARKS/ARGUMENTS

Entry of the foregoing amendment is requested. Claims 5-7 and 30 are presented for examination. Claims 1-4 and 17-28 are pending and withdrawn. Claims 8-16 and 29 have been canceled. Claim 30 is added herein.

Applicants have studied the Office Action of May 3, 2007 and see no need for the Examiner to repeat material such as points 5 and 6.

Regarding claim status and the remarks at the top of page 4, with all due respect, the Examiner misstates the facts.

Applicants' amendment was compliant based upon what their representative was told following the last telephonic interview. If the Examiner studies his summary of the interview, he says that the rejections under 35 U.S.C. § 112 and § 103 would be withdrawn. In fact they were. The Examiner did NOT say he was planning to enter new rejections. Hence, applicants had every reason to believe the application would be allowed. This being the case, paragraph 14 in the Office Action of May 4, 2006, became pertinent, and applicants acted in accordance with that statement, i.e., they amended non-elected process claims to depend from a claim that they believed would be allowed, based on what the Examiner said during the interview, and wrote in his remarks.

Hence, before the Examiner starts alleging non-compliance with the rules, he should review the entire record.

Turning to the rejections, these are confusing. The Examiner seeks to limit claims to SEQ ID NO: 1, failing to recognize that SEQ ID figure 1 delineates 14 peptides, all of which satisfy the dictates of claim 5. The Examiner is invited to review the discussion of figure 1 in the specification, and figure 1 itself. The rejection should be withdrawn.

Claims 6 and 8 have been amended (claim 6) or canceled (claim 8), to address what applicants believe is the rejection; however, they confess to finding the rejection confusing.

FAPESP 203 US (10026221)


It is believed that all rejections have been addressed and overcome. A Notice of Allowance which includes claims 1-4 and 17-28 as well as claims 5, 6, 7, and 30 is called for.

* * *

Please charge the extension fee due to our Deposit Account No. 06-2375, under Order No. FAPESP 203/10026221 from which the undersigned is authorized to draw.

Respectfully submitted,

By



Norman D. Hanson
Reg. No. 30,946
FULBRIGHT & JAWORSKI L.L.P.
666 Fifth Avenue, 31st Floor
New York, New York 10103-3198
(212) 318-3000
(212) 318-3400 (Fax)
Attorney for Applicant

Attachments: Extension of Time